Table 1 Clinicopathological associations of DNER expression in breast cancer.

From: DNER promotes epithelial–mesenchymal transition and prevents chemosensitivity through the Wnt/β-catenin pathway in breast cancer

Variables

Low

N = 92 (%)

High

N = 114 (%)

P value*

Age at diagnosis, years

  

0.664

≤50

21 (22.8)

29 (25.4)

 

>50

71 (77.2)

85 (74.6)

 

Grade

  

0.043

Well

17 (18.5)

9 (7.9)

 

Moderately

24 (26.1)

26 (22.8)

 

Poorly

51 (55.4)

79 (69.3)

 

Tumour size (cm)

  

0.073

≤2

47 (51.1)

44 (38.6)

 

>2

45 (48.9)

70 (61.4)

 

Lymph node metastasis

  

0.759

Negative

35 (38.0)

41 (36.0)

 

Positive

57 (62.0)

73 (64.0)

 

Vascular invasion

  

0.098

Negative

78 (84.8)

86 (75.4)

 

Positive

14 (15.2)

28 (24.6)

 

ER

  

0.152

Negative

69 (75.0)

75 (65.8)

 

Positive

23 (25.0)

39 (34.2)

 

PR

  

0.034

Negative

55 (59.8)

84 (73.7)

 

Positive

37 (40.2)

30 (26.3)

 

HER2

  

0.381

Negative

58 (63.0)

65 (57.0)

 

Positive

34 (37.0)

49 (43.0)

 

Ki67

  

0.535

<14 %

72 (78.3)

85 (74.6)

 

≥14 %

20 (21.7)

29 (25.4)

 

Recurrence

  

0.041

No

83(90.2)

91(79.8)

 

Yes

9(9.8)

23(20.2)

 
  1. *P values calculated by log-rank testing; bold if statistically significant, P < 0.05.
  2. ER oestrogen receptor, PR progesterone receptor, HER2 human epithelial growth factor receptor-2.